Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. Poseida has discovered and are developing a broad portfolio of product candidates in a variety of indications based on its core proprietary platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Its core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable Poseida Therapeutics to engineer its wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics.